Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dianthus Therapeutics (DNTH) Short-term Investments: 2017-2024

Historic Short-term Investments for Dianthus Therapeutics (DNTH) over the last 6 years, with Dec 2024 value amounting to $252.4 million.

  • Dianthus Therapeutics' Short-term Investments rose 40.08% to $346.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $346.6 million, marking a year-over-year increase of 40.08%. This contributed to the annual value of $252.4 million for FY2024, which is 509.88% up from last year.
  • Per Dianthus Therapeutics' latest filing, its Short-term Investments stood at $252.4 million for FY2024, which was up 509.88% from $41.4 million recorded in FY2023.
  • In the past 5 years, Dianthus Therapeutics' Short-term Investments registered a high of $252.4 million during FY2024, and its lowest value of $41.4 million during FY2023.
  • For the 3-year period, Dianthus Therapeutics' Short-term Investments averaged around $118.0 million, with its median value being $60.1 million (2022).
  • As far as peak fluctuations go, Dianthus Therapeutics' Short-term Investments crashed by 31.16% in 2023, and later spiked by 509.88% in 2024.
  • Yearly analysis of 3 years shows Dianthus Therapeutics' Short-term Investments stood at $60.1 million in 2022, then tumbled by 31.16% to $41.4 million in 2023, then surged by 509.88% to $252.4 million in 2024.